I am very happy reading your posts .
I really , very much hope that this means , that your doctor acquaintance ? — is / has used Bisantrene for their AML patients ??
( In Australia - if so, this can only be currently )
Truly thankful if this is so .
Do not concern-
I only want Bisantrene to have the chance to be back into treatment use , & be used in a very regular treatment way , in chemotherapy if it can save patients lives more, or cause them less harm and suffering.
Totally different although a related thing to traditional chemotherapy treatment use :-
*The FTO protein factor - is a patient specific ,individually significant factor ; which is fantastic in how it is now recognised .
The FTO protein is important and now being understood as a protein that if it is higher and over- expressed, is of significance for Bisantrene —as clearly in lab it has shown the most compellingly high specificity against this for anyone who is susceptible to their cancer ‘because’ of increased FTO Protein .
(*COH Study, 2020 results — Over 250000 drugs , agents tested against the FTO Protein specifically . )
As an important now recognised important cancer treatment target where it is relevant—the FTO protein :
* Bisantrene the No 1 !! out of over 250000 drugs tested specifically against the FTO Protein, was the best inhibitor .
“Genetics” — we coined a new phrase at work due to sentient health events too often observed .
So often , medical history and health events express as we see it , and arrive “like a freight train ... right on time” , at a certain age or in ‘type ‘of event. ( the ‘same as the parent’ )
Nature not nurture .
Not being negative , only something to understand.
Every individual is unique . And more is being understood all of the time .
With respect to the FTO Protein - for some people this is very relevant for . And it is not uncommon .
It is relevant for AML also .
*The FTO Protein expression , and it’s increasing — is very much associated with quite a number of cancers & is associated strongly with these cancers occurrence, but more importantly is associated with high morbidity .
So eg. AML is a harder to treat Leukaemia.
Many AML leukaemias are very difficult to treat - and there is high , terrible morbidity .
*There is a huge amount of research , globally , to seek to treat AML better , and to save more people’s lives .
AML , a subset , (?? the higher morbidity ones) - might be due to being associated with higher FTO Protein in the individual .
Likely this can be of importance - and if so , is a “why” for why Bisantrene can achieve a CR ,” remission” , where nothing else has fully knocked out the cancer or where these is nothing more standard -of -care wise that can be used and Bisantrene can be tried.
Anyway , I just want to see it back in the clinical armamentarium.
Without doubt in the greater picture — more .,and better , and moretargeted drug agents are very much needed in Oncology.
- Forums
- ASX - By Stock
- RAC
- RAC - Charts & Price Action
RAC - Charts & Price Action, page-1452
-
- There are more pages in this discussion • 20,092 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.61 |
Change
-0.040(2.42%) |
Mkt cap ! $274.2M |
Open | High | Low | Value | Volume |
$1.65 | $1.70 | $1.60 | $229.6K | 139.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 129 | $1.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.65 | 2839 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2044 | 1.600 |
1 | 5000 | 1.590 |
1 | 1158 | 1.585 |
3 | 16359 | 1.570 |
1 | 8000 | 1.560 |
Price($) | Vol. | No. |
---|---|---|
1.595 | 2732 | 1 |
1.650 | 2839 | 1 |
1.700 | 5000 | 1 |
1.715 | 1100 | 1 |
1.750 | 1500 | 1 |
Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |